Clinical review: idiopathic pulmonary fibrosis--past, present and future.
Idiopathic pulmonary fibrosis (IPF) is an important, and devastating, interstitial lung disease. It has a median mortality of only 3 years, worse than many cancers, and its incidence continues to rise. In this article, an overview of key developments in our understanding and clinical management of IPF will be provided.
Dempsey
Owen J
OJ
Interstitial Lung Disease Clinic, Department of Respiratory Medicine, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland, UK. owen.dempsey@nhs.net
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003348:Cortisone / Q000008:administration & dosage; D006801:Humans; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D003348:Cortisone